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The diagnosis of bone metastases in cervical cancer deﬁnes ad-
vanced disease with a median overall survival of b1 year (Matsuyama
et al., 1989; Abdul-Karimet al., 1990). Themost common bones affected
are the lumbar spine and pelvis; distal extremity metastases are rare,
accounting for b5% of bone metastases (Ratanatharathorn et al., 1994;
Rangarajan et al., 2010). High-dose palliative radiotherapy provides sig-
niﬁcant symptomatic relief in approximately 67% of cervical cancer pa-
tients (Matsuyama et al., 1989). The overall clinical and personal impact
of osseous fractures for patients highlights the importance of clearly de-
ﬁning the management plan for osseous metastases in gynecological
cancers.
We report a woman who presented with back and lower ex-
tremity pain, ultimately found to have cervical cancer. Despite mul-
timodal therapy, the patient passed away 3 months after her initial
presentation. This case report also reviews the biology of bone me-
tastases and presents some emerging therapeutic options for these
scenarios.⁎ Corresponding author at: Gynecologic Oncology, Obstetrics-Gynecology, USC Norris
Comprehensive Cancer Center, Women's Cancer Program, 1441 Eastlake Ave, Suite
7419, Los Angeles, CA 90033, USA. Fax: +1 323 442 7436.
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The patient was a previously healthy 36-year-old nulligravida
woman who presented with isolated back and right leg pain (RLE)
for twoweeks. Imagingworkup includedX-ray andmagnetic resonance
imaging (MRI) of the spine, which demonstrated multiple vertebral
body lesions with spinal canal extension at the T6 level (Fig. 1A);
Tc99m bone scan redemonstrated the multiple spine and RLE lesions,
including a large, distal right femoral lesion (Fig. 1B). Distal right ex-
tremity X-rays and MRI were obtained to exclude pathologic fracture
at this site (Fig. 1C). An anterior cortex, lytic lesion with associated
soft tissue component was seen, without associated fracture. A subse-
quent FDG-PET/CT (Fig. 1D) of the abdomen and pelvis demonstrated
multiple organ lesions and lymphadenopathy. Because the etiology of
the presumed diffusemetastatic diseasewas unclear, the patient subse-
quently underwent a CT-guided, core biopsy of the femur. Pathology
revealed sheets of undifferentiated pleomorphic neoplastic cells with
high nuclear/cytoplasmic (N:C) ratio, prominent nucleoli and nu-
merous mitotic ﬁgures (Figs. 2A–C). The tumor cells stained
strongly for cytokeratin (AE1/3) (Fig. 2D) and negative for CK7/
CK20, S100, HMB45, synaptophysin, chromogranin, estrogen re-
ceptor (ER), progesterone receptor (PR), thyroid transcription
factor-1 TTF1, CA125, renal cell marker, and calretinin. Because
the primary site was still unidentiﬁable, excisional biopsy of the
femur lesion was performed. Pathology showed rare areas of
squamous differentiation among nests of tumor cells immunore-
active for p63 (Fig. 2E) and CK5/6 (Fig. 2 F), consistent with a
poorly-differentiated squamous cell carcinoma from either the
lung, head and neck or uterine cervix. A pelvic examination re-
vealed a single 2-cm erosive lesion on her anterior cervix, and a
cervical biopsy demonstrated a moderately-to-poorly differentiat-
ed squamous cell carcinoma.
Zoledronic acid was administered to slow the progression of the
bone metastases, and surgical excision and internal ﬁxation were
performed to the femur. She also received palliative radiation therapy
(20 Gy over 5 fractions to T4–T7 and 8 Gy in a single fraction to
L5-sacrum). The patient received one cycle of systemic gemcitabine
(1600 mg/m2) with cisplatin (100 mg/m2). Although the thoracic spine
showed partial response to the palliative radiation on follow-up imaging
(Fig. 1E), multiple, new diffuse bone and soft tissue metastases were
found. The patient rapidly deteriorated and passed away before any fur-
ther chemotherapy could be offered.e.
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Fig. 1.MRI of the thoracic spine (A) shows multilevel vertebral body lesions (arrowheads), and compression fracture of the T6 vertebral body associated with epidural
extension (arrow); 99 mTc Bone Scan (B) demonstrates extensive spine and extremity bone lesions (arrowheads), including right femur (arrow); right knee X-ray
(C) and MRI (not shown) were obtained to exclude a pathologic fracture. An anterior cortex, lytic lesion with associated soft tissue component (*) was seen. No frac-
ture was demonstrated; FDG-PET/CT (D) revealed multiple lymph nodes, liver and renal metastases and conﬁrmed osteolytic metastases throughout the spine and
extremities. Post therapy MRI (E) demonstrates decreased epidural metastasis (arrow) at site of focused radiation; however the remainder of the spine is now dif-
fusely involved.
14 S.V. Dandapani et al. / Gynecologic Oncology Reports 5 (2013) 13–15Discussion
A review of the English literature in PubMed from1946 to 2012with
search terms of “gynecological cervical cancer,” and “bone metastases”
to identify cases with pathological fracture, distal extremity bone
metastases of unknown primary revealed 51 reports in the indexed
literature.
Unusual distal extremity bone metastases from previously
undiagnosed cancers are rare, and not previously reported for newly
diagnosed cervical cancer. Bone metastases of unknown primary in
women are typically attributed to occult breast cancer which portends
a more favorable prognosis compared to other visceral malignancies.
On the other hand, recurrent cervical cancer after prior treatment in-
volving central (e.g., calvarium, vertebrae) and distal (e.g., extremities)
osseous lesions has been reported (George and Lai, 1995; Dewdney and
Selvarajah, 2010; Mohanty et al., 2010).
The earliest series of skeletal metastases from recurrent cervical
cancer suggest that the lumbar spine and pelvic bones were the
most common sites, and only 1.5% developed metastases to the proxi-
mal long bones (Matsuyama et al., 1989). Despite palliative radiation
(30 Gy/10 fractions) followed by cisplatin-based chemotherapy, sur-
vival was uniformly less than 1 year. A subsequent series concluded
that the likelihood of bone metastases increased with advanced stage,
and survival after detecting the bone metastasis averaged only 6 months
(Abdul-Karim et al., 1990). A review of autopsy reports from that
series identiﬁed previously undiagnosed bone metastases in 18% of
patients suggesting that bone metastases may be under diagnosed
(Abdul-Karim et al., 1990). Across nearly all series, most patients re-
ceived palliative radiation (range of 16 Gy in 4 fractions; 55 Gy in 25
fractions, and most common regimen 30 Gy in 10 fractions) and 70%
reported pain relief.
The predilection for bone metastases to the lumbar spine and the
pelvic bones is thought to occur from hematogenous spread or via
Batson's plexus (Abdul-Karim et al., 1990). Most authors seem to agree
that the degree of differentiation predicts the likelihood of bonemetasta-
ses with poorly differentiated tumors faring the worst (Abdul-Karim et
al., 1990). Interestingly our patient's tumor in the pathological fracturewas poorly differentiated, whereas the primary cervical lesion was
moderately differentiated non-keratinizing. Aside from histologic mor-
phology, no biomarkers exist to better predict likelihood for osseous
metastases.
Chemotherapy options for metastatic cervical cancer typically in-
clude a cisplatin-based doublet; however, bone penetration by these
agents is generally poor (Ratanatharathorn et al., 1994). New treat-
ments for bone metastases from breast cancer may be evaluated for
cervical cancer patients. Currently, patients with bone metastases
from breast cancer are treated with a bisphosphonates and/or the
RANK-ligand inhibitor, denosumab, to slow and decrease the number
of skeletal-related events and fractures (NCCN, 2012). Although cancer
was historically regarded as organ-speciﬁc,most people nowappreciate
that biochemical processes and signaling pathways are likely shared
among solid cancers. Thus, research on metastatic breast cancer could
guide new treatment considerations for cervical cancer. Emerging
targets currently under investigation for bone metastases in breast
cancer (e.g., Cathepsin K, c-Src, sclerostin, or speciﬁc integrins) should
be investigated for cervical cancer patients as well (Coluzzi et al.,
2011). The proto-oncogene, c-Src, has already been implicated in trans-
lational studies in breast cancer as predictive of skeletal metastases ver-
sus visceral metastases and may represent a candidate therapeutic
target to explore in cervical cancer. Dasatinib is a small molecular
multi-tyrosine kinase inhibitor of the Src-family kinases (among
other targets), and has shown efﬁcacy in prostate cancer with
bone metastases. Bone sialoprotein, a marker originally identiﬁed
and validated as a predictive marker for skeletal metastases in
breast cancer, has also been found to be highly expressed in prima-
ry invasive squamous cell cervical cancers and may help to identify
patients at higher risk for skeletal metastases (Detry et al., 2003). In
this patient's case the burden of the disease was not able to be con-
trolled, and her case highlights the need for better treatments for
bone metastases in gynecological cancers.
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Fig. 2. Representative immunohistochemical staining images of tumor from femur bone biopsy. Hematoxylin and eosin (H&E) of initial femur biopsy at 4× (A), 10× (B), and 40×
(C) magniﬁcation. Triangle head indicates nucleoli and arrow indicates mitotic ﬁgures. (D) AE 1/3. (E) p63 staining. (F) CK 5/6.
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